Neo-DREAM Study Investigating Daromun for the Treatment of Clinical Stage IIIB/C Melanoma
- 20 September 2019
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 15 (32) , 3665-3674
Abstract
High-risk resectable melanoma poses therapeutic challenges as this subgroup remains most vulnerable for disease recurrence. Immunotherapy has established its efficacy in cases of advanced melanoma,...Keywords
This publication has 39 references indexed in Scilit:
- Cancer treatment and survivorship statistics, 2019CA: A Cancer Journal for Clinicians, 2019
- Targeted agents and immunotherapies: optimizing outcomes in melanomaNature Reviews Clinical Oncology, 2017
- Immune evasion in cancer: Mechanistic basis and therapeutic strategiesSeminars in Cancer Biology, 2015
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialThe Lancet, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009